By Chris Wack
BioCryst Pharmaceuticals shares were up 8% at $7.40 after the Institut national d’excellence en sante et services sociaux issued a positive recommendation for patients taking Orladeyo berotralstat to be reimbursed for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years of age and older in Quebec.
The stock hit its 52-week low of $6.62 on Aug. 8, and is down 44% in the past 12 months.
Health Canada authorized Orladeyo in June 2022 for the routine prevention of recurrent HAE attacks in patients 12 years and older.
In February 2023, the Canadian Agency for Drugs and Technologies in Health Canadian Drug Expert Committee issued a positive recommendation for Orladeyo.
Write to Chris Wack at [email protected]
Read the full article here